` PYC (PYC Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PYC
vs
S&P/ASX 300

Over the past 12 months, PYC has underperformed S&P/ASX 300, delivering a return of -14% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
PYC vs S&P/ASX 300

Loading
PYC
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
PYC vs S&P/ASX 300

Loading
PYC
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
PYC vs S&P/ASX 300

Loading
PYC
S&P/ASX 300
Add Stock

Competitors Performance
PYC Therapeutics Ltd vs Peers

S&P/ASX 300
PYC
ABBV
AMGN
GILD
VRTX
Add Stock

PYC Therapeutics Ltd
Glance View

Market Cap
670.7m AUD
Industry
Biotechnology

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

PYC Intrinsic Value
0.59 AUD
Overvaluation 48%
Intrinsic Value
Price
Back to Top